JP2010510243A - 三環系−ビス−エノン（ｔｂｅ）の合成および生物学的活性 - Google Patents

三環系−ビス−エノン（ｔｂｅ）の合成および生物学的活性 Download PDF

Info

Publication number
JP2010510243A
JP2010510243A JP2009537396A JP2009537396A JP2010510243A JP 2010510243 A JP2010510243 A JP 2010510243A JP 2009537396 A JP2009537396 A JP 2009537396A JP 2009537396 A JP2009537396 A JP 2009537396A JP 2010510243 A JP2010510243 A JP 2010510243A
Authority
JP
Japan
Prior art keywords
compound
cancer
tbe
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2009537396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010510243A5 (enExample
Inventor
忠士 本田
チトラ サンダララジャン
ゴードン ダブリュ． グリブル
マイケル ビー． スポーン
カレン ティー． リビー
Original Assignee
トラスティーズ オブ ダートマス カレッジ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トラスティーズ オブ ダートマス カレッジ filed Critical トラスティーズ オブ ダートマス カレッジ
Publication of JP2010510243A publication Critical patent/JP2010510243A/ja
Publication of JP2010510243A5 publication Critical patent/JP2010510243A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/743—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups having unsaturation outside the rings, e.g. humulones, lupulones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
JP2009537396A 2006-11-17 2007-11-16 三環系−ビス−エノン（ｔｂｅ）の合成および生物学的活性 Ceased JP2010510243A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86633006P 2006-11-17 2006-11-17
PCT/US2007/085010 WO2008064133A1 (en) 2006-11-17 2007-11-16 Synthesis and biological activities of new tricyclic-bis-enones (tbes)

Publications (2)

Publication Number Publication Date
JP2010510243A true JP2010510243A (ja) 2010-04-02
JP2010510243A5 JP2010510243A5 (enExample) 2011-01-13

Family

ID=39171447

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009537396A Ceased JP2010510243A (ja) 2006-11-17 2007-11-16 三環系−ビス−エノン（ｔｂｅ）の合成および生物学的活性

Country Status (5)

Country Link
US (2) US7714012B2 (enExample)
EP (1) EP2094651A1 (enExample)
JP (1) JP2010510243A (enExample)
CA (1) CA2670099A1 (enExample)
WO (1) WO2008064133A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
EP2094651A1 (en) * 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
US8299046B2 (en) * 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
US20090048205A1 (en) * 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
ME03529B (me) 2008-01-11 2020-04-20 Reata Pharmaceuticals Inc Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti
US9189794B2 (en) * 2008-02-11 2015-11-17 Goldspot Media, Inc. Method and apparatus for maximizing brand exposure in a minimal mobile display
CA2721665C (en) 2008-04-18 2017-01-24 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
WO2009146216A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
CN102083442B (zh) 2008-04-18 2014-08-13 里亚塔医药公司 抗氧化剂炎症调节剂：在c-17具有氨基和其它修饰的齐墩果酸衍生物
SI2271658T1 (sl) 2008-04-18 2017-03-31 Reata Pharmaceuticals, Inc. Antioksidantni modulatorji vnetja: C-17 homologirani derivati oleanolne kisline
EP2279197B1 (en) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
ES2449396T3 (es) 2008-07-22 2014-03-19 Trustees Of Dartmouth College Cianoenonas monocíclicas y métodos de uso de las mismas
WO2010053817A1 (en) * 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
EP3121509B1 (en) 2009-07-21 2018-06-13 3M Innovative Properties Company Light assembly
ES2574606T3 (es) * 2009-11-26 2016-06-21 National Taiwan University Una sustancia activa contra el cáncer de Antrodia camphorata, método de preparación de la misma y uso de la misma
EP2558105B1 (en) 2010-04-12 2019-11-20 Reata Pharmaceuticals, Inc. Bardoxolone methyl for the treatment of obesity
CA2822071C (en) 2010-12-17 2019-07-16 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
HUE044081T2 (hu) 2011-03-11 2019-09-30 Reata Pharmaceuticals Inc C4 Monometil-triterpenoid-származékok, és módszerek azok alkalmazására
EP2556827A1 (en) * 2011-08-11 2013-02-13 Acadia Pharmaceuticals Inc. Treatment of neurodegenerative diseases
BR112014026640B1 (pt) 2012-04-27 2021-05-18 Reata Pharmaceuticals, Inc compostos derivados de 2,2-difluoropropionamida de metil bardoxolona, formas polimórficas, composição farmacêutica, e uso dos mesmos
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
CN102670796A (zh) * 2012-05-22 2012-09-19 广西天天乐药业股份有限公司 一种治疗脾胃虚弱的中药及其制备方法
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
RS59194B1 (sr) 2012-09-10 2019-10-31 Reata Pharmaceuticals Inc C17-alkandiilni i alkendiilni derivati oleanolne kiseline i metode za njihovu upotrebu
WO2014148455A1 (ja) 2013-03-19 2014-09-25 第一三共株式会社 テルペノイド誘導体
AR096046A1 (es) 2013-04-24 2015-12-02 Abbvie Inc Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
MD4274C1 (ro) * 2013-05-27 2014-09-30 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Azotat de trans-bis(dimetilglioximato)bis(nicotinamid)cobalt(III)dihidrat, ce manifestă proprietăţi antioxidante la plante
SG10201906113RA (en) 2013-08-23 2019-08-27 Reata Pharmaceuticals Inc Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
US9290455B2 (en) 2014-02-11 2016-03-22 Trustees Of Dartmouth College CDDO-Me amino acid conjugates and methods of use
US11059792B2 (en) 2015-02-12 2021-07-13 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant inflammation modulators
US10233146B2 (en) * 2015-04-16 2019-03-19 The Research Foundation For The State University Of New York Acetylenic cyanoenones as therapeutics for inflammation and carcinogenesis
BR112018005861B1 (pt) 2015-09-23 2022-11-22 Reata Pharmaceuticals, Inc Compostos derivados de ácido oleanólico modificado com c4 para a inibição de il-17, composição farmacêutica e usos terapêuticos dos ditos compostos
CA3042123A1 (en) 2016-11-08 2018-05-17 Reata Pharmaceuticals, Inc. Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
US11993574B2 (en) 2018-06-15 2024-05-28 Reata Pharmaceuticals, Inc Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma
WO2019246461A1 (en) 2018-06-20 2019-12-26 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
AU2020222080C1 (en) * 2019-02-15 2022-09-29 Glaxosmithkline Intellectual Property Development Limited Hydroxypyridoxazepines as Nrf2 activators
CN120248001A (zh) 2019-07-19 2025-07-04 里亚塔医药公司 C17极性的-取代的杂芳族合成三萜类化合物及其使用方法
EP4146226A1 (en) 2020-05-09 2023-03-15 Reata Pharmaceuticals Holdings, LLC Methods of treating covid-19 using bardoxolone methyl or analogs thereof
AU2021397631A1 (en) 2020-12-11 2023-07-20 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059339A1 (en) * 2002-01-15 2003-07-24 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
JP2003534248A (ja) * 2000-04-12 2003-11-18 シエーリング アクチエンゲゼルシャフト 選択的活性エストロゲンとしての８β−ヒドロカルビル置換エストラトリエン

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ATE92499T1 (de) 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
PT86377B (pt) 1986-12-24 1990-11-20 Lilly Co Eli Processo para a preparacao de conjugados de imunoglobulinas com um difluoronucleosideo acilado
ES2075040T3 (es) 1988-02-16 1995-10-01 Lilly Co Eli 2',3'-dideoxi-2',2'-difluoronucleosidos.
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
CA2004695C (en) 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
WO1991015498A2 (en) 1990-04-04 1991-10-17 Nycomed Imaging As Nucleoside derivatives
SE502569C2 (sv) 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
UA41261C2 (uk) 1992-06-22 2001-09-17 Елі Ліллі Енд Компані Спосіб одержання збагачених бета-аномером нуклеозидів
US5606048A (en) 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
YU43193A (sh) 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
US5401838A (en) 1992-06-22 1995-03-28 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
DE4308042C2 (de) 1993-03-13 2000-10-12 Alstom Energy Syst Gmbh Wälzmühle
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US5972703A (en) 1994-08-12 1999-10-26 The Regents Of The University Of Michigan Bone precursor cells: compositions and methods
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
PT909184E (pt) 1996-07-03 2004-02-27 Upjohn Co Libertacao de farmaco para um alvo utilizando derivados de sulfonamida
WO1998032762A1 (en) 1997-01-24 1998-07-30 Norsk Hydro Asa Gemcitabine derivatives
US20050276836A1 (en) 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6485756B1 (en) 1999-04-06 2002-11-26 Collaborative Technologies, Inc. Stable, homogeneous natural product extracts containing polar and apolar fractions
CN1361760A (zh) 1999-05-14 2002-07-31 尼瑞斯药品公司 新的白介素－1和肿瘤坏死因子－α调节剂、所述调节剂的合成以及使用所述调节剂的方法
CA2341263C (en) 1999-06-25 2006-08-01 Roche Diagnostics Corporation Enzyme inhibition immunoassay
WO2002003996A1 (en) 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
WO2002047611A2 (en) 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
JP2005514359A (ja) 2001-11-23 2005-05-19 中外製薬株式会社 腫瘍を標的とする酵素の同定法
CA2485565A1 (en) 2002-05-13 2004-08-05 Trustees Of Dartmouth College Inhibitors and methods of use thereof
EP1567169A4 (en) 2002-11-04 2009-10-21 Xenoport Inc GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
WO2005042002A2 (en) 2003-10-30 2005-05-12 Entelos, Inc. Treatment of rhematoid arthritis with flip antagonists
US8288439B2 (en) 2003-11-04 2012-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the inhibition of HIV-1 replication
JP5087400B2 (ja) 2004-09-07 2012-12-05 パシフィック アロー リミテッド アンゲロイル基を有する抗腫瘍化合物
DE102005004161A1 (de) 2005-01-28 2006-09-14 Kabushiki Kaisha Tokai Rika Denki Seisakusho Schlitzeinrichtung und intelligente Zündanlage
EP1959969A2 (en) 2005-07-01 2008-08-27 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
DE102005041613A1 (de) 2005-09-01 2007-03-08 Ergonex Pharma Gmbh Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom
JP5558719B2 (ja) 2005-12-12 2014-07-23 モサメディックス・ビー．ブイ． 治療および診断におけるプレターゲッティングに適したアネキシン誘導体
US8299046B2 (en) 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
EP2094651A1 (en) * 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
JP2008247898A (ja) 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US20090048205A1 (en) 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534248A (ja) * 2000-04-12 2003-11-18 シエーリング アクチエンゲゼルシャフト 選択的活性エストロゲンとしての８β−ヒドロカルビル置換エストラトリエン
WO2003059339A1 (en) * 2002-01-15 2003-07-24 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5009016483; ＨＯＮＤＡ: ＪＯＵＲＮＡＬ　ＯＦ　ＯＲＧＡＮＩＣ　ＣＨＥＭＩＳＴＲＹ Ｖ７１　Ｎ８, 20060315, Ｐ３３１４-３３１６ *
JPN6013007056; Ｏｒｇａｎｉｃ　＆　Ｂｉｏｍｏｌｅｃｕｌａｒ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．１，　Ｎｏ．２４, ｐ．４３８４-４３９１　（２００３）． *

Also Published As

Publication number Publication date
WO2008064133A1 (en) 2008-05-29
US7714012B2 (en) 2010-05-11
US20110009363A1 (en) 2011-01-13
EP2094651A1 (en) 2009-09-02
WO2008064133A9 (en) 2008-07-31
CA2670099A1 (en) 2008-05-29
US8067394B2 (en) 2011-11-29
US20080261985A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
JP2010510243A (ja) 三環系−ビス−エノン（ｔｂｅ）の合成および生物学的活性
US8067465B2 (en) Tricyclic-bis-enone derivatives and methods of use thereof
JP2006515859A (ja) 阻害剤およびその使用法
AU679754B2 (en) Arylidene and heteroarylidene oxindole derivatives as tyrosine kinase inhibitors
US20090048205A1 (en) Combination therapy with synthetic triterpenoids and gemcitabine
AU2011306068B2 (en) Methods and compositions for treating lung cancer
JP2015007070A (ja) 経口で生物学的に利用できるコーヒー酸関連抗癌剤
WO2008136838A1 (en) Novel amide derivatives of cddo and methods of use thereof
NO318648B1 (no) Anvendelse av 6-substituerte acylfulvenanaloger som har antitumorvirkning
JP2008531558A (ja) 新規なリポオキシゲナーゼ阻害剤
KR101975299B1 (ko) 인돌아세트산의 코어구조를 함유하는 화합물 및 그의 용도
JP2020507567A (ja) 置換グリシン化合物の共結晶およびそれの使用
TW201912627A (zh) 氘原子取代的吲哚甲醯胺類衍生物、其製備方法及其在醫藥上的應用
EP3922628A1 (fr) Composes cytotoxiques inhibiteurs de la polymerisation de la tubuline
WO2003078386A1 (en) Naphthylsemicarbazone, naphthylhydrazone, naphthylthiosemicarbazone, and naphthylthiohydrazone compounds and therapeutic use thereof
US8809395B2 (en) Methods for making valerenic acid derivatives and their use
EP3560914A1 (en) Sulfonyl amidine as indoleamine-2,3-dioxygenase inhibitor, and preparation method therefor and use thereof
JPS61227568A (ja) 新規３‐ピリジルメチルナフチル誘導体およびそれらの製法
EP4067367B1 (en) Oleanane cinnamamide derivative, preparation method therefor, and use thereof
IL321907A (en) pparg modulators
WO2001089504A1 (fr) Derives de tropolone et compositions pharmaceutiques
EP3947382A1 (en) Compounds for uses in pharmacological induction of hbf for treatment of sickle cell disease and beta-thalassemia
Chen Synthesis and biological evaluation of two classes of promising, curcumin-inspired anticancer agents
WO2013107278A1 (zh) 酮类与吲哚衍生物反应合成的新型抗癌化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101115

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130212

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130218

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20130620